The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Those of us quietly sitting on the sidelines know not to get too excited about these rises likewise don’t get too depressed about any falls. I’m waiting like others for the golden RNS before the champers gets cracked open
Me thinks that tweet should have been a RNS as it will affect the sp. Could be knuckles being wrapped?
Big volume trades to start the day. Not sure what the rumour might be?
Most of my stocks dropped below my purchase price at some stage. Just need to trust your research and focus on the fundamentals. No news and no income often equals a slow drift down in the sp. Secret is not to put all your monies into that initial purchase, save some for the drop!
Don’t be so negative. Just be selective in what you read. I’ve often found new avenues for research from ideas I’ve read on forums. Just switch to thread view to quickly filter through what you want.
Sorry chaps but the vaccine hasn’t even entered human clinical trials- expected mid 2021. Can’t get that excited about PDSBio- maybe that’s why it’s sp has tanked. Folks in the know understand a lot can still go wrong at this early stage. Despite all that I’m still looking at an entry point Into PDSBio so not upset about it’s recent fall.
Makes no sense PDSBio is tanking and nsci is rocketing!
‘ Monday will see a scramble for shares under £1.......once the strategy of using UK built lateral flow tests is announced. Limited choices with ABDX amongst the front runners imo’
If I had a pound for every time I heard that I wouldn’t need to invest in shares.
My humble opinion is it’s rare at some time in the near future not to find the sp lower than your entry level.
Antibody test could pave way for mass travel, says expert
A revolutionary antibody test being used to track down the source of Covid may also open the door to an “immunity passport” that would allow mass travel and boost international trade, according to one of the world’s leading emerging diseases scientists.
The pioneering kit known as “cPass” detects within 90 minutes whether someone has antibodies that neutralise Covid. Late last year it became the first of its kind to receive authorisation from the United States Food and Drug Administration and it is also permitted within the European Union.
It was invented by a team led by Professor Wang Linfa, director of the emerging infectious diseases programme at Duke-NUS Medical School in Singapore. It tests the blood for neutralising antibodies, which prevent Covid from infecting a patient’s cells and act as a biomarker for immunity.
Scientists are working on a version of the test that would require a simple finger prick, similar to the one used by diabetics to check blood sugar levels.
While no method is 100 per cent infallible, testing for neutralising antibodies would offer a safer benchmark for reopening mass travel than relying on vaccinations. “Scientifically, I would say it is the only way out, regardless of whether you are infected or immunised,” said Prof Wang.